treatment. During rhGH treatment, frequent control of serum PTH level is necessary. Background. The aim of the study was to assess the requirement of active vitamin D in dialysed children Keywords: alfacalcidol; alkaline phosphatase; children; during treatment with recombinant human growth end-stage renal failure; growth hormone; growth hormone (rhGH ).
Introduction measured in two groups of patients studied in the years 1994-1995 (group I ) and 1995-1998 (group II ) respectively. Group I received a constant dose of Growth retardation is one of the major problems in alfacalcidol that was sufficient to keep PTH below children with chronic renal failure (CRF ). Treatment 200 pg/ml before rhGH treatment began. The serum with recombinant human growth hormone (rhGH ) PTH level was checked every 3 months. Alfacalcidol improves growth velocity in these patients [1] [2] [3] [4] [5] . Data was administered to group II according to serum PTH on the influence of growth hormone on bone metabollevels checked on a monthly basis.
ism in children with CRF are limited [5] [6] [7] . The Results. In group I the PTH level increased after 3 question whether renal osteodystrophy, a typical conand 6 months of rhGH treatment from mean level sequence of CRF, increases the risk of occurrence or 73±60; 155±156 and 344±249 pg/ml respectively; aggravation of calcium and active vitamin D metabol-P<0. 05 . AP activity increased after 6 months of ite deficiency during accelerated growth in response to treatment from 206±99 to 325±124 U/l respectively; growth hormone treatment remains unanswered.
P<0.01. The calcium level decreased from baseline
The aim of the study was to determine changes in after 3 months of treatment from 2.36±0.21 to the requirement for vitamin D metabolites in dialysed 2.17±0.12 mmol/l respectively; P<0.05. In group II children during the first 6 months of rhGH treatment. AP activity increased after 3 and 6 months of treatment from 272±169 to 332±192 and 404.9±219.8 U/l Subjects and methods respectively; P<0.01. The mean level of phosphorus decreased after 6 months from 2.15±0.28 to 1.70±0.39 mmol/l respectively; P<0.01. In group II Twenty-six dialysed children, 10 on haemodialysis (HD) and 16 on continuous ambulatory peritoneal dialysis (CAPD), the mean dose of alfacalcidol increased by 60.9%.
were included in the study. Patients were divided into two Conclusions. In children with end-stage renal failure, groups according to different alfacalcidol dosage. Fourteen higher doses of vitamin D are needed during rhGH children (group I ) aged 8.2-13.9 with a mean age of 11.2 years (seven on HD and seven on CAPD) were observed in below 200 pg/ml. Patients received alfacalcidol in daily oral in biochemical parameters between patients treated doses except when PTH level increased to above 300 pg/ml. with HD and CAPD. However, after analysing all HD In these cases intermittent oral doses were given two or three patients from groups I and II together and all CAPD times per week. Calcium carbonate was used in both groups patients from group I and II together, we observed as the only phosphate binder. In both groups it was adjusted significant differences in AP activity during treatment every month to maintain a serum phosphorus level from 1.4 compared with results obtained before treatment. to 1.9 mmol/l. All of the patients were treated with rhGH at Mean values in the HD group before treatment and at a dose of 1-1.1 IU/kg/week administered in six or seven 3 and 6 months were 206±118 U/l, 247.8±108 U/l subcutaneous injections per week. and 370±201.6 U/l respectively. The differences All patients underwent transiliac bone biopsy following tetracycline labelling before rhGH treatment. Histo-between: before treatment versus 3 months, before morphometric assessment according to the recommendations treatment versus 6 months and 3 months versus 6 of the American Society of Bone and Mineral Research was months of treatment were all significant. Mean values performed [8] .
in the CAPD group before treatment and at 3 and 6 Hyperparathyroidism was diagnosed when osteoid volume months were 255.9±148.8 U/l, 319.1±163.2 U/l and to bone volume (OV/BV ) was >3%, bone formation rate to 357.2±164.7 U/l respectively. The differences between: tissue volume referent (BFR/TV ) >600 mm3/mm2/day and before treatment versus 3 months, before treatment mineralization lag time (Mlt) was <25 days. Osteomalacia versus 6 months and 3 months versus 6 months of was diagnosed when OV/BV >11% and BFR/TV treatment were all significant. There was no significant <400 mm3/mm2/day. Mixed lesion was diagnosed when difference in the mean dose of alfacalcidol at the start OV/BV was >11%, BFR/TV was >400 mm3/mm2/day, and Mlt was >25 days. Adynamic bone disease was diagnosed of rhGH treatment between groups I and II when OV/BV <11% and BFR/TV <210 mm3/mm2/day. (0.076±0.03 and 0.092±0.021 mg/kg/week respectNormal bone histology (NB) was indicated when OV/BV ively). After 6 months of treatment, the dose in group was 2-11% and BFR/TV was 210-600 mm3/mm2/day. II significantly increased to 0.148±0.05 mg/kg/week Osteoporosis (OP) was characterized by significant lowering (P<0.01).
of trabecular bone volume without excessive quantity of In all patients, an increase in growth velocity was osteoid and a BFR/TV below 210 mm3/mm2/day.
observed. In group I, the mean value of growth velocity In group I the serum concentrations of intact PTH were before rhGH treatment was 1.1±0.8 cm per 6 months measured at baseline and every 3 months, and alkaline and during treatment, it was 3.79±1.11 cm per 6 phosphatase activity (AP), calcium, and phosphorus were months (P<0.05). In group II, the mean value of determined monthly during rhGH treatment. In group II, the serum levels of PTH, AP activity, calcium, and phos-growth velocity before rhGH treatment was phorus were measured monthly. The results are shown in 1.08±1.17 cm per 6 months, and during treatment it 3-month intervals for both groups. Serum PTH level was was 4.49±1.65 cm per 6 months (P<0.05). There was determined by immunoradiometric method (INCSTAR Co., no significant difference between groups before and Rochester, Minnesota; laboratory reference value during rhGH treatment. The mean value of growth 10-55 pg/ml ), AP activity was determined by the kinetic velocity per 6 months in patients with adynamic bone method ( laboratory reference value 100-280 U/l ), and serum disease was 4.5 cm, and it was 5.5 cm, 4.1 cm, 3.9 cm levels of calcium and phosphorus were determined by routine and 4.4 cm in hyperparathyroidism, normal bone histolaboratory methods.
logy, mixed lesion and osteomalacia respectively. There was no significant difference between growth velocity Statistics in patients with different types of renal osteodystrophy. Many factors influence calcium-phosphorus homeostasis and bone metabolism, e.g. PTH, vitamin D meta-
Results
bolites, and growth hormone. Growth hormone directly, or through insulin-like growth factor ( IGF-1), has a stimulatory effect on osteoblasts and osteoclasts The results of bone biopsies before rhGH treatment in group I revealed adynamic bone disease in five patients, [9] . In patients with ESRD, decreased tissue or cell response to growth hormone and decreased synthesis hyperparathyroidism in three, normal bone histology in four, mixed lesion in one, and osteoporosis in one of vitamin D metabolites was noted. Calcitriol is a very important factor for normal mineralization of patient. The results in group II were: adynamic bone disease in three patients, hyperparathyroidism in four, bone tissue [10] . Because of the differing densities of vitamin D receptors, which depend on hyperparathynormal bone histology in three, mixed lesion in one, and osteomalacia in one patient. No significant differ-roidism type, polymorphism of the receptor gene, and decreased relation of calcitriol to the receptors, the ences in the prevalence of particular types of renal osteodystrophy in either group were found. dose of vitamin D necessary to maintain the PTH level below 200 pg/ml is different in each patient with endMean values of serum PTH, calcium, phosphorus concentrations, and AP activity in both groups are stage renal disease.
The optimal dose of vitamin D necessary to maintain shown in Table 1 . There were no significant differences the PTH level below 200 pg/ml in children with end-patients revealed a significant rise in the serum phosphorus concentration [11] . The same was found by stage renal failure who are treated with rhGH is
Hansen et al. [12] in adult patients with growth horunclear. After 6 months of rhGH treatment, there was mone deficiency. In our investigations, serum phosa significant rise in the serum PTH level in the patients phorus levels decreased in patients who received high in group I, i.e. those whose alfacalcidol dose before alfacalcidol doses. This was probably caused by an treatment was sufficient to maintain the PTH level increase in the amount of calcium carbonate ingested below 200 pg/ml and was unchanged during treatment.
by group II children, whose initial serum concentraThis was accompanied by a decrease in serum calcium tions were higher than those in group I patients. It is levels after 3 months of rhGH treatment. In group II, difficult to analyse these findings because absorption in which the alfacalcidol dose was adjusted monthly of phosphorus is influenced by alfacalcidol, calcium to maintain the PTH levels below 200 pg/ml, it was carbonate doses, and also by the amount of phosnecessary to increase the alfacalcidol dose by about phorus in the diet. The heterogeneity of skeletal lesions 60%. It seems that accelerated growth during growth in the population studied makes it more difficult to hormone treatment leads to an increased demand for interpret the biochemical findings. According to Joffe calcium and active vitamin D metabolites. This points et al.
[13], it is not possible to evaluate precisely the to the necessity of frequent control of PTH, calcium osteodystrophy type on the basis of non-invasive and phosphorus levels and an appropriate adjustment examinations. of the alfacalcidol and calcium carbonate doses.
In our 6-month study, there was no difference in The initial dose of vitamin D in children undergoing growth hormone effects between patients with different rhGH treatment is difficult to establish. Determining types of renal osteodystrophy treated with growth the type of renal osteodystrophy by bone biopsy may hormone. In a 1-year observation period of children be helpful in choosing the initial dose of active vitamin with end-stage renal disease not treated with growth D metabolite in particular cases. Nonetheless, even the hormone, Kuizon et al. noted significantly diminished diagnosis of adynamic bone disease in a biopsy taken growth in children with adynamic bone [14] . There is before starting rhGH treatment and subsequent rapid not enough data in the literature to evaluate the growth does not justify withdrawal of active vitamin importance of the type of renal osteodystrophy for the D supplementation. Intensive growth occurs even in growth velocity in children with end-stage renal disease these cases, leading to an elevated demand for calcium treated with growth hormone. and active vitamin D metabolites.
The AP activity increased in the majority of patients during rhGH therapy. Increased AP activity during Conclusions rhGH treatment of children with CRF, both those dialysed and those managed conservatively, has also (i) An increase in the requirements of calcium and been found by other authors [2, 3, 11] . The high AP active metabolites of vitamin D was observed during activity observed in most of our patients is probably a rhGH therapy in children with CRF. (ii) According consequence not only of high PTH serum concentra-to dynamic changes in PTH serum level during rhGH tion but also of activation of osteoblasts by growth therapy, frequent control is necessary in order to keep hormone. In a multicentre study, no significant changes PTH serum concentration below 200 pg/ml. in the AP activity and calcium and phosphorus serum levels were found after 2 years of rhGH treatment References compared to a control group [1]. In our study, the mean value of serum phosphorus did not increase
